OraSure Technologies Inc (OraSure) develops, manufactures, and distributes oral fluid diagnostic, collection devices and other diagnostic products for detection and diagnosis of critical medical conditions. Its product portfolio encompasses around infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; Ebola virus, Zika virus and antigens for influenza type A and type B. OraSure also sells immunoassay tests and reagents for insurance risk assessment, substance-abuse testing and forensic toxicology applications; and products for the cryosurgical removal of warts and several other benign skin lesions. The company distributes its products to hospitals, clinics, community-based organizations and other public health organizations, distributors, clinical laboratories, and commercial and industrial entities. The company sells its products through distributors in the Americas, Europe and Asia-Pacific region. OraSure is headquartered in Bethlehem, Pennsylvania, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company OraSure Technologies Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
OraSure Technologies Inc Company Overview
OraSure Technologies Inc Company Snapshot
OraSure Technologies Inc Pipeline Products and Ongoing Clinical Trials Overview
OraSure Technologies Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
OraSure Technologies Inc, Recent Developments
Nov 07, 2023: OraSure Reports Q3 ‘23 Revenue of $89.2 Million; Core Revenue Grows 7% Year-over-Year
Aug 03, 2023: OraSure Reports Q2 ‘23 Revenue of $85.4 Million; Core Revenue Grows 3% Year-over-Year
Jun 13, 2023: Study Concludes Self-Sampling Using Colli-Pee Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access
May 10, 2023: OraSure Reports 1Q23 record revenue of $155.0 million announces new collaborations as company increasingly focuses on core growth
Mar 27, 2023: nRichDX and OraSure advance commercial collaboration to create preanalytical solutions for the Urine-based MDx Market
Nov 08, 2022: OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year
Nov 03, 2022: OraSure Technologies receives general clearance for its ORAcollect•Dx device for Over-the Counter (OTC) use from the U.S. Food and Drug Administration (FDA)
Nov 02, 2022: InteliSwab COVID-19 rapid test now available in Amazon’s online store
Nov 02, 2022: DNA Genotek receives additional 510(k) clearance for ORAcollect.Dx
Sep 28, 2022: OraSure Technologies receives $8.6 million BARDA contract to develop 2nd generation ebola test